<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449187</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-1310-102-FE</org_study_id>
    <nct_id>NCT02449187</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, crossover study to investigate the effect of food on
      the pharmacokinetics of JLP-1310 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, crossover clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">March 9, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(last)</measure>
    <time_frame>48 hours from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(inf)</measure>
    <time_frame>48 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>48 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>48 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>48 hours from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>JLP-1310, Fasted followed by fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JLP-1310 dosing in the fasted state followed by fed dosing
Interventions:
Drug: JLP-1310</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JLP-1310, Fed followed by fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JLP-1310 dosing in the fasted state followed by fed dosing
Interventions:
Drug: JLP-1310</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JLP-1310, Fasted followed by fed</intervention_name>
    <description>In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.</description>
    <arm_group_label>JLP-1310, Fasted followed by fed</arm_group_label>
    <other_name>metformin hydrochloride, rosuvastatin calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JLP-1310, Fed followed by fasted</intervention_name>
    <description>In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.</description>
    <arm_group_label>JLP-1310, Fed followed by fasted</arm_group_label>
    <other_name>metformin hydrochloride, rosuvastatin calcium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer, age is over 19 years

          2. Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5
             kg/m2 , no more than 30.5 kg/m2

          3. Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial

          4. Subject who has the ability and willingness to participate the whole period of trial

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in kidney, liver, cardiovascular system, respiratory system,
             endocrine system, or neuropsychiatric system.

          2. Subjects who are allergic to investigational drug.

          3. Subjects who have a medical history which can affect the clinical trial.

          4. Hypertension(Systolic BP ≥ 140mmHG or Diastolic BP ≥ 90mmHg), Liver enzyme (AST, ALT)
             level exceeds the maximum normal range more than one and a half times.

          5. History of drug abuse or positive drug screening.

          6. Participation in other drug studies within 3 months prior to the drug administration.

          7. Whole blood donation within 60 days, blood component donation within 30 days or who
             got transfusion within 30days.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Heon Cho, MD., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

